Capital Research Global Investors Maintains Stake in LivaNova PLC (LIVN)
Capital Research Global Investors continued to hold its stake in LivaNova PLC (NASDAQ:LIVN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,650,000 shares of the company’s stock at the close of the second quarter. Capital Research Global Investors owned approximately 3.42% of LivaNova PLC worth $100,997,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its stake in LivaNova PLC by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after buying an additional 153 shares during the last quarter. Riverhead Capital Management LLC boosted its stake in LivaNova PLC by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after buying an additional 763 shares during the last quarter. Exane Derivatives boosted its stake in LivaNova PLC by 814.8% during the second quarter. Exane Derivatives now owns 3,156 shares of the company’s stock valued at $158,000 after buying an additional 2,811 shares during the last quarter. Teacher Retirement System of Texas bought a new position in LivaNova PLC during the second quarter valued at approximately $204,000. Finally, LS Investment Advisors LLC boosted its stake in LivaNova PLC by 14.5% during the second quarter. LS Investment Advisors LLC now owns 3,449 shares of the company’s stock valued at $211,000 after buying an additional 436 shares during the last quarter. 82.26% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Capital Research Global Investors Maintains Stake in LivaNova PLC (LIVN)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/capital-research-global-investors-maintains-stake-in-livanova-plc-livn.html.
Shares of LivaNova PLC (LIVN) opened at 73.62 on Friday. LivaNova PLC has a 12 month low of $40.83 and a 12 month high of $73.75. The stock has a market capitalization of $3.60 billion, a P/E ratio of 131.46 and a beta of 0.59. The firm’s 50-day moving average price is $66.06 and its 200-day moving average price is $59.60.
LivaNova PLC (NASDAQ:LIVN) last issued its earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.19. The business had revenue of $321.40 million for the quarter, compared to analysts’ expectations of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The firm’s quarterly revenue was up .1% on a year-over-year basis. On average, equities research analysts forecast that LivaNova PLC will post $3.25 EPS for the current year.
A number of brokerages recently commented on LIVN. Berenberg Bank reissued a “buy” rating and set a $70.00 price target on shares of LivaNova PLC in a research note on Friday, August 11th. Jefferies Group LLC increased their price target on LivaNova PLC from $76.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Needham & Company LLC raised LivaNova PLC from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research note on Friday, September 15th. Canaccord Genuity reissued a “hold” rating and set a $71.00 price target on shares of LivaNova PLC in a research note on Wednesday, September 20th. Finally, BidaskClub lowered LivaNova PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. LivaNova PLC has a consensus rating of “Hold” and a consensus target price of $71.50.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $60.76, for a total transaction of $60,760.00. Following the transaction, the director now directly owns 58,296 shares in the company, valued at approximately $3,542,064.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 3,000 shares of company stock worth $190,860. Insiders own 0.28% of the company’s stock.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Stock Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related stocks with our FREE daily email newsletter.